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 The objective of the present study to develop controlled release tablets of 
Metoprolol  succinate  using  Natural  polymer,  guar  gum  and  synthetic 
polymer, carbopol as a rate controlling polymers.. It was also desired to study 
the  effect  of  polymer  concentration.  Metoprolol  succinate,  β1-  selective 
adrenergic  receptor-  blocking  agent  used  in  the  management  of 
hypertension,  angina  pectoris,  cardiac  arrthymias,  myocardial  infarction, 
heart failure, hyperthyroidism and in the prophylactic treatment of migraine. 
The half-life of drug is relatively short approximately 4-6 hrs and in normal 
course  of  therapy  drug  administration  is  required  every  4-6  hrs,  thus 
warrants the use of controlled release formulation for prolong action and to 
improve patient compliance. In the present investigation Natural polymer, 
guar  gum  and  synthetic  polymer,  carbopol  have  been  selected  as  matrix 
forming materials for the drug. The formulations are made by employing the 
conventional  wet  granulation  method,  to  achieve  prolonged  release  of 
medicaments. 
INTRODUCTION:  Over  the  past  30  years,  as  the 
expense and complication involved in marketing new 
drug  entities  have  increased,  with  concomitant 
recognition  of  the  therapeutic  advantages  of 
controlled  drug  delivery,  greater  attention  has  been 
focused  on  development  of  sustained  release  or 
controlled  release  drug  delivery  systems.  The 
attractiveness  of  these  dosage  forms  is  due  to 
awareness to toxicity and ineffectiveness of drug when 
administered or applied by conventional dosage form 
of tablets, capsules, injectables, ointments etc.  
Usually  conventional  dosage  forms  produce  wide 
ranging fluctuation in drug concentration in the blood 
stream and tissue with consequent undesirable toxicity 
and poor efficiency. This factor as well as factors such 
as repetitive dosing and unpredictable absorption led 
to the concept of controlled drug delivery system.  
The goal in designing sustained or controlled delivery 
system is to reduce the frequency of the dosing or to 
increase effectiveness of the drug by localization at the 
site of action, reducing the dose required or providing 
uniform drug delivery.  
So,  the  controlled  release  dosage  form  is  a  dosage 
form that release one or more drugs continuously in a 
predetermined  pattern  for  a  fixed  period  of  time, 
either  systemically  or  to  a  specified  target  organ. 
Controlled  release  dosage  forms  provide  a  better 
control of plasma drug levels, less dosage frequency, 
less  side  effects,  increased  efficacy  and  constant 
delivery. 
Drug Profile: 
Metoprolol  Succinate:  Metoprolol  Succinate  ((±)-1-
(isopropylamino)-3-[p-(2-methoxyethyl)  phenoxy]-2-
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propanol  succinate  (2:1)  Molecular  Formula  is 
(C15H25NO3)2• C4H6O4.  Metoprolol succinate is a white 
crystalline powder. It is freely soluble in water; soluble 
in  methanol;  sparingly  soluble  in  ethanol;  slightly 
soluble in dichloromethane and 2-propanol; practically 
insoluble  in  ethyl  acetate,  acetone,  diethylether  and 
heptane.  
 
Metoprolol  is  a  beta1-selective  (cardioselective) 
adrenergic  receptor  blocking  agent.  This  preferential 
effect is not absolute, however, and at higher plasma 
concentrations,  metoprolol  also  inhibits  beta2-
adrenoreceptors, chiefly located in the bronchial and 
vascular  musculature.  Metoprolol  has  no  intrinsic 
sympathomimetic  activity,  and  membrane-stabilizing 
activity  is  detectable  only  at  plasma  concentrations 
much greater than required for beta-blockade. Animal 
and  human  experiments  indicate  that  metoprolol 
slows  the  sinus  rate  and  decreases  AV  nodal 
conduction.  
Clinical  pharmacology  studies  have  confirmed  the 
beta-blocking activity of metoprolol in man, as shown 
by reduction in heart rate and cardiac output at rest 
and upon exercise, reduction of systolic blood pressure 
upon  exercise,  inhibition  of  isoproterenol-induced 
tachycardia,  and  reduction  of  reflex  orthostatic 
tachycardia. Prescribed dose is 25 mg to 100 mg daily 
in  a  single  dose,  whether  used  alone  or  added  to  a 
diuretic. The dosage may be increased at weekly (or 
longer)  intervals  until  optimum  blood  pressure 
reduction is achieved. In general, the maximum effect 
of any given dosage level will be apparent after 1 week 
of therapy. Dosages above 400 mg per day have not 
been studied. 
MATERIALS AND METHOD: 
Construction  of  Calibration  Curve  for  Metoprolol 
Succinate:  Accurately  weighed  100mg  of  Metoprolol 
succinate  was  dissolved  in  methanol  in  a100ml 
volumetric  flask  and  the  solution  was  made  up  to 
volume with methanol. 
The  standard  solution  of  Metoprolol  succinate  was 
subsequently diluted with phosphate buffer of pH 6.8 
to obtain a series of dilutions containing 2, 4, 6, 8 and 
10 µg of Metoprolol succinate per 1 ml of solution. The 
absorbance  of  the  above  dilutions  was  measured  in 
Shimadzu double beam UV spectrophotometer at 275 
nm using the phosphate buffer of pH 6.8 as a blank. 
The  concentrations  of  Metoprolol  succinate  and  the 
corresponding absorbance values are given Table 1.1. 
The  absorbance  values  were  plotted  against 
concentrations of Metoprolol succinate as shown in Fig 
1.1.  The  method  obeyed  Beer’s  law  in  the 
concentrations range of 0-10 µg/ml. 
Preparation  of  Tablets  using  Guar  Gum  by  Wet 
Granulation  Method:  Different  formulations  were 
prepared by wet granulation method. The amount of 
drug was kept constant at 50mg/tablet. The amount of 
polymer in these formulations varies from 25, 30, 35, 
40,  45  and  50%  w/w.  The  final  tablet  weight  was 
adjusted  to  240mg  by  adding  lactose  as  filler.  The 
different  composition  of  the  tablet  formulations  are 
given in table 1. 
All the powders were first passed through sieve no.20. 
Required quantity of drug, polymer and lactose were 
mixed thoroughly and transferred into mortar and PVP 
K30  dissolved  in  Isopropyl  alcohol  was  added  with 
constant  mixing.  The  wet  mass  was  passed  through 
sieve no. 10 and the obtained granules dried for 2 hrs 
in an  oven at 40
oC. The  dried granules were passed 
through  a  sieve  no.  12.  Finally  magnesium  stearate 
(1%w/w) and talc (1%w/w) was mixed for lubrication 
and glidant for granules. The obtained granules were 
then compressed with single punch tablet compression 
machine  (Cadmach,  Ahmadabad,  India)  using  9mm 
punches and dies.  
Preparation  of  Tablets  using  Carbopol-934  by  Wet 
Granulation  Method:  Different  formulations  were 
prepared by wet granulation method. The amount of 
drug was kept constant at 50mg/tablet. The amount of 
polymer in these formulations varies from 5, 10, 15, 
20,  25  and  30%  w/w.  The  final  tablet  weight  was 
adjusted to 240mg by adding lactose as filler.  All the 
powders  were  first  passed  through  sieve  no.  20. 
Required quantity of drug, polymer and lactose were 
mixed thoroughly and transferred into mortar and PVP 
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constant  mixing.  The  wet  mass  was  passed  through 
sieve no. 10 and the obtained granules dried for 2 hrs 
in an  oven at 40
oC. The  dried granules were passed 
through  a  sieve  no.  12.  Finally  magnesium  stearate 
(1%w/w) and talc (1%w/w) was mixed for lubrication 
and Glidant for granules. The obtained granules were 
then compressed with single punch tablet compression 
machine  (Cadmach,  Ahmadabad,  India)  using  9mm 
punches and dies.  
TABLE 1.1: FORMULATIONS OF TABLETS 
Ingredients 
Formulation Code 
A1  A2  A3  A4  A5  A6  B1  B2  B3  B4  B5  B6 
Metoprolol succinate  50  50  50  50  50  50  50  50  50  50  50  50 
Guar gum(25-50%w/w)  60  72  84  96  108  120  -  -  -  -  -  - 
Carbopol-934(5-30%w/w)  -  -  -  -  -  -  12  24  36  48  60  72 
Lactose  115.6  103.6  91.6  79.6  67.6  55.6  163.6  151.6  139.6  127.6  115.6  103.6 
PVP K30  7.2  7.2  7.2  7.2  7.2  7.2  7.2  7.2  7.2  7.2  7.2  7.2 
Isopropyl Alcohol  Q.S  Q.S  Q.S  Q.S  Q.S  Q.S  Q.S  Q.S  Q.S  Q.S  Q.S  Q.S 
Magnesium Stearate  2.4  2.4  2.4  2.4  2.4  2.4  2.4  2.4  2.4  2.4  2.4  2.4 
Talc  4.8  4.8  4.8  4.8  4.8  4.8  4.8  4.8  4.8  4.8  4.8  4.8 
Total Weight (mg)  240  240  240  240  240  240  240  240  240  240  240  240 
  
Evaluation of Granules: (Table 2)  
Angle of Repose: The angle of repose of granules was 
determined by the fixed funnel method. The accurately 
weighed granules were taken into a funnel. The height 
of the funnel was adjusted in such a way that the tip of 
the funnel just touches the apex of the heap of the 
granules. The granules were allowed to flow through 
the funnel freely onto the surface. The diameter of the 
powder cone was measured and angle of repose was 
calculated by using the following equation:  
Tan  = h/r 
Where h = height, r = radius of the powder cone.  
Bulk  Density:    Both  loose  bulk  density  (LBD)  and 
tapped bulk density (TBD) were determined. A quantity 
of  powder  from  each  formulation  into  a  100mL 
graduated  cylinder.  After  the  initial  volume  was 
observed,  the  cylinder  was  fixed  on  the  density 
apparatus and the time knob was set for tapping and 
measured  the  final  volume  after  tapping.  The  bulk 
density of the powder was calculated.  
LBD  and  TBD  were  calculated  using  the  following 
formulas:  
LBD= weight of the powder/volume of the packing 
TBD= weight of the powder/tapped volume of the packing 
Compressibility  Index:  Compressibility  index  is  an 
important measure that can be obtained from the bulk 
and tapped densities. In theory, the less compressible 
a material the more flowable it is. A material having 
values of less than 20 to 30% is defined as the free 
flowing material. 
TBD - LBD          
Carr’s index (%) =               X 100  
     TBD  
TABLE 1.2: EVALUATION OF GRANULES  
Formulation code  Angle of repose ()  Loose bulk density (g/mL)  Tapped bulk density (g/mL)  Compressibility index (%)  Hausner’s ratio 
A1  23.699±0.013  0.497±0.011  0.531±0.010  6.403±0.021  1.068±0.041 
A2  24.139±0.022  0.477±0.021  0.508±0.011  5.731±0.032  1.061±0.012 
A3  24.546±0.011  0.458±0.042  0.486±0.021  5.761±0.041  1.061±0.011 
A4  25.371±0.023  0.466±0.051  0.494±0.031  5.668±0.040  1.060±0.013 
A5  26.331±0.024  0.446±0.043  0.471±0.036  5.307±0.012  1.056±0.048 
A6  27.613±0.030  0.469±0.041  0.497±0.062  5.633±0.011  1.059±0.054 
B1  19.093±0.020  0.458±0.013  0.485±0.053  5.567±0.010  1.059±0.062 
B2  23.734±0.014  0.465±0.014  0.492±0.047  5.488±0.016  1.058±0.051 
B3  24.764±0.010  0.442±0.032  0.467±0.028  5.353±0.027  1.056±0.034 
B4  26.552±0.013  0.434±0.034  0.458±0.018  5.240±0.029  1.055±0.041 
B5  27.463±0.011  0.428±0.041  0.451±0.016  5.099±0.031  1.054±0.010 
B6  29.234±0.014  0.432±0.052  0.479±0.046  9.812±0.030  1.108±0.016 
All values are expressed as Mean± SD, n=3 
Evaluation of Tablets:   Thickness:  The  thickness  of  the  tablets  was 
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each  batch  were  used,  and  average  values  were 
calculated. Results were shown in table 1.3. 
Hardness:  Hardness  of  the  tablet  was  determined 
using  the  Monsanto  hardness  tester.  The  lower 
plunger  was  placed  in  constant  with  the  tablet  and 
zero reading was taken. The plunger was then forced 
against  a  spring  by  tuning  a  threaded  bolt  until  the 
tablet  is  fractured.  As  the  spring  was  compressed  a 
pointer rides along a gauge in the barrel to indicate the 
force. The results were showed in the table 1.3. 
Weight Variation Test: Formulated matrix tablets were 
tested for weight uniformity, 20 tablets were weighed 
collectively  and  individually.  From  the  collective 
weight,  average  weight  was  calculated  by  using  the 
following formula.  
        Average Weight - Individual Weight 
% Weight Variation =                   X 100 
          Average Weight 
The Results were shown in table 1.3. 
Friability: The Roche friability test apparatus was used 
to  determine  the  friability  of  the  tablets.  20  pre-
weighed  tablets  were  placed  in  the  apparatus  and 
operated for 100 revolutions and then the tablets were 
reweighed.  The  percentage  friability  was  calculated 
according  to  the  following  formula.  Results  were 
shown in table 1.3. 
Initial wt. of Tablets – Final wt. of Tablets 
Friability (%) =                       X 100 
 Initial wt. of Tablets 
Drug  Content:  Twenty  tablets  of  each  formulation 
were collected and powdered. Powder equivalent to 
100mg  of  Metoprolol  succinate  was  weighed  and 
added  to  5ml  of  methanol  and  diluted  with  6.8 
phosphate buffer make up the volume to 100ml it was 
allowed  to  sonication  for  15min.  The  solution  was 
filtered  and  the  absorbance  was  measured  with 
suitable  dilutions  by  using  Shimdzu  UV 
spectrophotometer at 275nm. Results were shown in 
table 1.3 
TABLE 1.2: EVALUATION OF TABLETS 
Formulation code  Thickness* (mm)  Hardness* (kg/cm
2)  Friability** (%)  Weight variation *** (%)  Drug content* (%) 
A1  4.71±0.01  4.4 ±0.156  0.75 ±0.011  2.161±0.045  98.33±0.051 
A2  4.70±0.02  4.6 ±0.114  0.88 ±0.021  2.951±0.173  98.80±0.051 
A3  4.66±0.02  4.1 ±0.245  0.82 ±0.032  3.527±0.416  99.45±0.034 
A4  4.72±0.02  4.3 ±0.112  0.85 ±0.010  3.367±0.174  98.23±0.069 
A5  4.70±0.03  4.0 ±0.158  0.76 ±0.022  2.758±0.192  98.48±0.086 
A6  4.67±0.03  4.7 ±0.312  0.72 ±0.033  4.159±0.057  98.72±0.415 
B1  4.72±0.03  4.8 ±0.158  0.71 ±0.041  2.469±0.127  97.78±0.173 
B2  4.71±0.02  5.0 ±0.315  0.68 ±0.054  2.494±0.066  98.59±0.173 
B3  4.69±0.01  4.9 ±0.214  0.55 ±0.025  3.095±0.071  96.99±0.051 
B4  4.72±0.02  4.2 ±0.132  0.81 ±0.028  2.585±0.053  99.76±0.069 
B5  4.72±0.03  4.3 ±0.161  0.67 ±0.016  3.199±0.064  98.78±0.259 
B6  4.69±0.03  4.5 ±0.102  0.77 ±0.019  4.151±0.053  98.14±0.219 
All values are expressed as Mean± SD; * n=3; ** n=10, and *** n=2 
In-Vitro  Dissolution  Study:  The  in  vitro  dissolution 
study  was  carried  out  using  USP  Type  II  dissolution 
apparatus. The study was carried out in 900 mL of 0.1N 
HCl for first 2 hours and then 900 mL of  phosphate 
buffer  (pH  6.8)  from  3  to  12  hr.  The  dissolution 
medium was kept in thermostatically controlled water 
bath, maintained at 37±0.5
oC. The paddle was lowered 
so that the lower end of the stirrer was 25 mm above 
from  the  base  of  the  beaker.  The  tablet  was  then 
introduced into the dissolution jar and the paddle was 
rotated at 75 rpm.  
At  different  time  intervals,  5  mL  sample  was 
withdrawn  and  analyzed  by  using  spectrophoto- 
metrically at 275 nm, and using pH 6.8 as a blank for 
the drug release. At each time of withdrawal, 5 mL of 
fresh  dissolution  medium  was  replaced  into  the 
dissolution flask.  
Infrared Spectroscopy: Infrared (IR) spectroscopy was 
conducted  using  a  Shimadzu  FTIR  8300 
Spectrophotometer (Shimadzu, Tokyo, Japan) and the 
spectrum  was  recorded  in  the  wavelength  region  of 
4000  to  400  cm
−1.  The  procedure  consisted  of 
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excipients)  in  KBr  and  compressing  into  discs  by 
applying a pressure. The pellet was placed in the light 
path and the spectrum was obtained. 
TABLE 1.4: DISSOLUTION DATA OF METOPROLOL SUCCINATE TABLETS FORMULATED WITH GUAR GUM 
Time 
Percentage of Metoprolol Released ( x ± s d ) 
A1  A2  A3  A4  A5  A6 
0.5  2.003 0.06  1.9520.04  1.8850.04  1.7160.02  1.6480.03  1.5980.02 
1  2.6210.04  2.5030.08  2.4180.06  2.2480.02  2.130006  1.9950.04 
1.5  3.1920.07  3.1070.06  2.9880.02  2.8850.06  2.6480.09  2.4440.08 
2  3.8340.12  3.7480.03  3.6620.08  3.5420.04  3.326.0.02  3.0650.07 
2.5  10.787±0.28  10.617±0.48  10.277±0.19  9.886±0.06  9.326±0.24  9.086±0.38 
3  12.6520.36  12.5310.56  11.6330.22  11.1220.24  10.2710.36  9.9970.24 
3.5  18.027±0.06  16.674±0.44  12.878±0.36  12.583±0.02  11.222±0.64  10.541±0.52 
4  20.8250.16  19.6330.42  18.0850.34  13.8660.62  11.9910.42  11.1720.46 
4.5  26.674±0.18  22.933±0.38  19.895±0.25  16.151±0.08  12.765±0.24  11.773±0.56 
5  31.3740.28  24.0770.66  24.0390.22  20.2740.52  13.4420.32  12.2410.48 
5.5  34.075±0.32  26.232±0.26  24.194±0.44  22.409±0.54  14.088±0.48  12.881±0.36 
6  36.2220.44  28.5670.42  29.3720.36  24.0480.36  18.3400.56  13.5070.28 
6.5  40.531±0.58  31.251±0.18  29.061±0.54  25.696±0.42  19.788±0.36  14.254±0.08 
7  44.7980.66  34.7930.24  34.7640.46  27.8590.28  21.244.0.42  16.7690.12 
7.5  49.762±0.24  37.679±0.08  35.988±0.42  29.358±0.32  22.820±0.22  19.220±0.52 
8  54.4150.32  40.5800.34  42.4080.28  31.2020.24  24.1790.24  20.8410.48 
8.5  58.250±0.70  44.496±0.36  43.515±0.22  33.392±0.42  25.657±0.26  22.470±0.74 
9  62.7780.12  46.7640.48  50.8120.24  35.0880.54  27.3120.28  24.1080.64 
9.5  66.824±0.26  51.061±0.24  49.108±0.34  37.636±0.36  29.144±0.24  25.585±0.56 
10  69.879.0.08  55.3810.12  55.2460.52  40.3650.48  31.3220.32  26.9020.42 
10.5  72.948±0.24  59.723±0.36  57.057±0.28  42.603±0.46  33.343±0.48  28.393±0.26 
11  76.8760.32  64.2560.48  59.3830.24  44.8510.42  35.0370.54  29.8920.42 
11.5  80.824±0.08  67.813±0.22  61.438±0.22  47.280±0.32  36.571±0.62  31.567±0.36 
12  84.9600.08  72.2120.12  63.5600.32  49.7210.24  38.1120.36  33.2510.24 
 
RESULTS AND DISCUSSION: 
TABLE  1:  CALIBRATION  CURVE  FOR  THE  ESTIMATION  OF  THE 
METOPROLOL SUCCINATE 
Concentration (µg/ml)  Absorbance (x¯ ±s d) 
0  0 
2  0.057 ± 0.002 
4  0.108 ± 0.003 
6  0.158 ± 0.003 
8  0.219 ± 0.004 
10  0.266 ± 0.002 
 
 
FIG.  1:  CALIBRATION  CURVE  FOR  THE  ESTIMATION  OF 
METOPROLOL SUCCINATE 
 
FIG.  1.2:  DISSOLUTION  PROFILES  OFMETOPROLOL  SUCCINATE 
TABLETS FORMULATED WITH GUAR GUM 
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FIG:  1.3  ZERO  ORDER  PLOTS  OF  METOPROLOL  SUCCINATE 
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FIG:  1.4  PEPPAS  PLOTS  OF  METOPROLOL  SUCCINATE  TABLETS 
FORMULATED WITH GUAR GUM 
TABLE 1.5: DISSOLUTION KINETICS OF METOPROLOL SUCCINATE TABLETS FORMULATED WITH GUAR GUM 
Formulations 
Correlation coefficient 
K value (mg/hr)  T50 (hr)  T90 (hr)  N 
Zero order  First order  Matrix  Peppas 
A1  0.9958  0.9311  0.8728  0.9837  6.7358  7.4  13.4  1.3788 
A2  0.9858  0.9366  0.8691  0.9824  5.4095  9.2  16.6  1.2830 
A3  0.9902  0.9674  0.8809  0.9828  5.2566  9.5  17.1  1.2958 
A4  0.9881  0.9841  0.9007  0.9818  3.9971  12.5  22.5  1.1894 
A5  0.9945  0.9868  0.9014  0.9813  3.0827  16.2  29.2  1.0965 
A6  0.9903  0.9841  0.9011  0.9761  2.6472  18.9  34.0  1.0432 
TABLE 1.6: DISSOLUTION DATA OF METOPROLOL SUCCINATE TABLETS FORMULATED WITH CARBOPOL-934 
Time 
Percentage of Metoprolol Released (x ± s d) 
B1  B2  B3  B4  B5  B6 
0.5  2.323±0.01  2.053±0.06  2.019±0.02  1.716±0.06  1.648±0.02  1.598±0.06 
1  3.348±0.03  3.144±0.02  2.958±0.04  2.872±0.04  2.636±0.04  2.501±0.08 
1.5  4.547±0.05  4.325±0.04  4.206±0.04  3.934±0.02  3.781±0.02  3.442±0.06 
2  5.449±0.02  5.159±0.02  4.988±0.08  4.833±0.06  4.476±0.06  4.254±0.02 
2.5  11.332±0.56  11.293±0.63  10.329±0.42  9.279±0.12  9.105±0.36  8.865±0.15 
3  12.930±0.36  12.941±0.24  11.769±0.36  10.342±0.26  10.336±0.31  9.555±0.21 
3.5  19.178±0.53  18.385±0.36  12.896±0.44  11.411±0.24  11.186±0.51  10.164±0.28 
4  23.219±0.35  21.522±0.48  18.104±0.54  12.603±0.22  12.124±0.52  10.945±0.17 
4.5  26.720±0.41  24.002±0.04  20.227±0.24  13.852±0.32  13.084±0.07  11.629±0.15 
5  31.251±0.18  26.831±0.52  22.361±0.03  18.896±0.24  13.998±0.08  12.248±0.25 
5.5  35.638±0.22  29.845±0.36  24.507±0.36  20.686±0.34  16.597±0.03  12.787±0.35 
6  39.711±0.35  32.874±0.24  27.339±0.24  22.822±0.36  18.711±0.27  13.631±0.41 
6.5  44.987±0.18  36.088±0.16  30.691±0.08  24.801±0.21  20.161±0.35  14.210±0.56 
7  50.290±0.25  39.318±0.43  33.387±0.06  26.959±0.20  21.450±0.21  16.775±0.63 
7.5  53.766±0.27  42.566±0.12  35.928±0.12  28.622±0.18  22.746±0.19  18.889±0.43 
8  57.260±0.41  45.999±0.42  38.819±0.24  30.799±0.16  24.217±0.12  20.339±0.41 
8.5  61.728±0.14  49.450±0.43  40.883±0.48  31.976±0.14  25.189±0.11  21.629±0.21 
9  66.163±0.56  53.088±0.58  43.968±0.54  34.001±0.32  26.504±0.15  22.924±0.24 
9.5  69.720±0.45  56.744±0.55  46.395±0.34  35.700±0.36  27.656±0.17  24.226±0.36 
10  73.802±0.14  60.587±0.42  50.520±0.32  37.913±0.42  28.983±0.37  25.198±0.48 
10.5  78.241±0.19  64.619±0.23  53.487±0.40  40.137±0.48  30.653±0.33  26.680±0.54 
11  82.197±0.21  68.166±0.18  57.312±0.18  42.204±0.50  32.669±0.26  27.832±0.15 
11.5  85.836±0.22  71.730±0.08  60.987±0.22  45.462±0.15  34.696±0.25  29.159±0.16 
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FIG:  1.5  DISSOLUTION  PROFILES  OF  METOPROLOL  SUCCINATE 
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FIG:  1.6  ZERO  ORDER  PLOTS  OF  METOPROLOL  SUCCINATE 
TABLETS FORMULATED WITH CARBOPOL-934 
 
FIG: 1.7: PEPPAS PLOTS OF METOPROLOL SUCCINATE TABLETS 
FORMULATED WITH CARBOPOL-934 
 
FIG:  1.8  DISSOLUTION  PROFILES  OF  METOPROLOL  SUCCINATE 
TABLET & MARKETED TABLET 
 
FIG:  1.9  ZERO  ORDER  PLOTS  OF  METOPROLOL  SUCCINATE 
TABLET & MARKETED TABLET 
 
FIG: 1.10 PEPPAS PLOTS OF METOPROLOL SUCCINATE TABLET & 
MARKETED TABLET 
TABLE: 1.7 DISSOLUTION KINETICS OF METOPROLOL SUCCINATE TABLET FORMULATED WITH CARBOPOL-934 
Formulations 
Correlation coefficient 
K value (mg/hr)  T50 (hr)  T90 (hr)  n 
Zero order  First order  Matrix  Peppas 
B1  0.9977  0.9362  0.8758  0.9945  6.9122  7.2  13.0  1.2972 
B2  0.9925  0.9518  0.8838  0.9909  5.8946  8.5  15.3  1.2460 
B3  0.9922  0.9626  0.8830  0.9920  4.9423  10.1  18.2  1.1897 
B4  0.9959  0.9839  0.8989  0.9880  3.8055  13.1  23.7  1.1121 
B5  0.9888  0.9953  0.9233  0.9935  2.9874  16.7  30.1  1.0124 
B6  0.9942  0.9918  0.9197  0.9900  2.5232  19.8  35.7  0.9551 
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TABLE:  1.8  DISSOLUTION  DATA  OF  METOPROLOL  SUCCINATE 
TABLET & MARKETED TABLET 
Time (hr) 
Percent of Metoprolol Released (X± S D) 
Formulated (B1)  Marketed 
0.5  2.323±0.01  2.88±0.03 
1  3.348±0.03  3.823±0.05 
1.5  4.547±0.05  4.806±0.02 
2  5.449±0.02  5.659±0.07 
2.5  11.332±0.56  11.661±0.22 
3  12.930±0.36  13.024±0.31 
3.5  19.178±0.53  20.931±0.35 
4  23.219±0.35  29.986±0.27 
4.5  26.720±0.41  38.247±0.21 
5  31.251±0.18  47.239±0.18 
5.5  35.638±0.22  56.937±0.11 
6  39.711±0.35  67.537±0.36 
6.5  44.987±0.18  72.796±0.33 
7  50.290±0.25  80.107±0.10 
7.5  53.766±0.27  84.902±0.19 
8  57.260±0.41  89.252±0.26 
8.5  61.728±0.14  93.587±0.32 
9  66.163±0.56  97.643±0.25 
9.5  69.720±0.45  - 
10  73.802±0.14  - 
10.5  78.241±0.19  - 
11  82.197±0.21  - 
11.5  85.836±0.22  - 
12  89.323±0.33  - 
 
DISCUSSION: The present investigation was carried out 
on the formulation and evaluation of oral controlled 
release  tablets  of  Metoprolol  succinate,  which  is 
having  a  short  biological  half-life  and  meant  for 
treatment of Hypertension, Angina pectoris and Heart 
failure. Matrix tablets containing drug and polymer are 
one of the simplest approaches for controlled release 
of  drug.  In  the  present  investigation  tablets  were 
prepared  by  wet  granulation  method.  The  Synthetic 
polymer,  Carbopol  and  Natural  polymer,  Guar  gum 
were used as a rate controlling polymers. Though they 
were  used  in  the  preparation  of  matrix  tablets,  the 
influence of polymer nature and concentration on the 
properties of the tablets were investigated. 
Evaluation  of  Granules:  The  granules  of  different 
formulations A1, A2, A3, A4, A5, andA6 were evaluated 
for  angle  of  repose,  LBD,  TBD,  compressibility  index 
and Hausner’s ratio. The results were reported in table 
1.2. 
From the above studies, the results of angle of repose 
(<30)  indicate  good  flow  properties  of  the  granules. 
This  was  further  supported  by  compressibility  index 
(<15),  also  Hausner’s  ratio  (<1.25).  All  these  results 
indicate that the granules having free flowing nature. 
 The granules of different formulations B1, B2, B3, B4, 
B5,  andB6  were  evaluated  for  angle  of  repose,  LBD, 
TBD,  compressibility  index  and  Hausner’s  ratio.  The 
results were reported in table 1.2. 
 From the above studies, the results of angle of repose 
(<30)  indicate  good  flow  properties  of  the  granules. 
This  was  further  supported  by  compressibility  index 
(<15),  also  Hausner’s  ratio  (<1.25).  All  these  results 
indicate that the granules having free flowing nature. 
Evaluation of Tablets: The results of physicochemical 
evaluation of tablets for the formulations A1, A2, A3, 
A4, A5, andA6 are shown in table 1.3. 
From the above results, all the formulations showed 
uniform  thickness,  hardness  of  the  tablets  was 
satisfactory  and  the  percentage  friability  for  all  the 
formulations was below 1% indicating that friability is 
within the prescribed  limits. Good and uniform drug 
content  (>98%)  was  observed  within  the  batches  of 
different  tablet  formulations.  The  results  of 
physicochemical  evaluation  of  tablets  for  the 
formulations B1, B2, B3, B4, B5, andB6 are shown in 
table 1.3. 
From the above results, all the formulations showed 
uniform  thickness,  hardness  of  the  tablets  was 
satisfactory  and  the  percentage  friability  for  all  the 
formulations was below 1% indicating that friability is 
within the prescribed  limits. Good and uniform drug 
content  (>98%)  was  observed  within  the  batches  of 
different tablet formulations. 
In  vitro  Dissolution  Studies:  The  results  of  in  vitro 
release studies for the formulations A1, A2, A3, A4, A5, 
and A6 in 0.1 N HCL for first 2hrs and next 3-12 hrs in 
6.8 phosphate buffer. The data was depicted in table 
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TABLE: 5.9 DISSOLUTION KINETICS OF METOPROLOL SUCCINATE TABLET & MARKETED TABLET 
Formulations 
Correlation coefficient 
K value (mg/hr)  T50 (hr)  T90 (hr)  n 
Zero order  First order  Matrix  Peppas 
Formulated (B1)  0.9977  0.9362  0.8758  0.9945  6.9122  7.2  13.0  1.2972 
Marketed  0.9843  0.8497  0.8318  0.9698  10.3250  4.8  8.7  1.4787 
 
The  drug  release  from  formulations  followed  zero 
order  kinetics,  as  the  plot  observed  in  between 
amount  of  drug  released  Vs  time  (fig.  1.3),  the 
corresponding  release  rate  constant  values  were 
shown in table 1.5. To ascertain mechanism of drug 
release from the above formulations plots log % drug 
released Vs log time were plotted (fig. 1.4). The release 
data  analyzed  as  Peppas  equation,  value  of  ‘n’  was 
found to be in the range of 1.0432 to 1.3788 indicating 
that  these  fallow  nonfickian  diffusion  mechanism  of 
drug. 
The above results indicated increasing concentration of 
Guar gum content the drug released was retarded. 
The  results  of  in  vitro  release  studies  for  the 
formulations B1, B2, B3, B4, B5, andB6 in 0.1 N HCL for 
first 2hrs and next 3-12hrs in 6.8 phosphate buffer. The 
data was depicted in table 1.6. 
The  drug  release  from  formulations  followed  zero 
order  kinetics,  as  the  plot  observed  in  between 
amount  of  drug  released  Vs  time  (fig.  1.6),  the 
corresponding  release  rate  constant  values  were 
shown in table 1.7. To ascertain mechanism of drug 
release from the above formulations plots log % drug 
released Vs log time were plotted (fig. 1.7). The release 
data  analyzed  as  Peppas  equation,  value  of  ‘n’  was 
found to be in the range of 0.9551 to 1.2972 indicating 
that  these  follow  nonfickian  diffusion  mechanism  of 
drug. 
The above results indicating, increasing concentration 
of Carbopol-934 content drug release was retarded. 
FTIR: The possible interaction between the Metoprolol 
succinate  and  the  polymers  such  as  Guar  gum  and 
Carbopol-934 was studied by IR spectroscopy. The IR 
spectra for Metoprolol succinate, Guar gum, Carbopol-
934 and its physical mixtures are shown in Figure. 
Pure Metoprolol succinate showed.  
C-O Str (1
o Alcohol)  :  1045.52cm
-1 
C-O Str in C-O-C  :   1110.84 cm
-1 
C-O Str in C=C-O-C  :   1238.39 cm
-1 
C=C Ring Str    :   1563.06 cm
-1 
N-C Str     : 3147.67 cm
-1 wave number as 
major peaks 
In the mixture of Metoprolol succinate and Guar gum, 
a peak observed with pure Metoprolol succinate was 
present at the same range showed below. 
C-O Str (1
o Alcohol)  :   1048.17 cm
-1 
C-O Str in C-O-C  :   1110.06 cm
-1 
C-O Str in C=C-O-C  :     1238.04 cm
-1 
C=C Ring Str    :   1562.12 cm
-1 
N-C Str     :  3151.23 cm
-1 
In the mixture of Metoprolol succinate and Carbopol-
934, a peak observed with pure Metoprolol succinate 
was present at the same range showed below. 
C-O Str (1
o Alcohol)  :  1039.38cm
-1 
C-O Str in C-O-C  :  1110.70 cm
-1 
C-O Str in C=C-O-C  :  1236.81 cm
-1 
C=C Ring Str    :  1563.05 cm
-1 
N-C Str     :  3148.67 cm
-1 
The results revealed no considerable changes in the IR 
peaks  of  Metoprolol  succinate  when  mixed  with 
excipients  compared  to  pure  Metoprolol  succinate. 
These  observations  indicated  the  incompatibility  of 
Guar  gum  and  Carbopol-934  with  Metoprolol 
succinate. The FTIR studies revealed that there is no 
interaction between drug and polymers. 
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CONCLUSION:  The  objective  of  the  present  study  to 
develop  controlled  release  tablets  of  Metoprolol 
succinate  using  Natural  polymer,  guar  gum  and 
synthetic  polymer,  Carbopol  as  a  rate  controlling 
polymers. The formulations were made by employing 
conventional wet granulation method. The granules for 
tablets  prepared  according  to  the  formulas  given, 
granulation  is  a  key  process  in  the  production  of 
dosage form involving the controlled release of a drug 
from matrix type particles. Micromeritic properties of 
granules  such  as  angle  of  repose,  LBD,  TBD,  and 
compressibility index for evaluated. The results were 
found to be within the specified limits of I.P. 
The  tablets  of  different  formulations  made  were 
subjected  to  evaluation  test,  such  as  thickness, 
hardness, friability, weight variation, and drug content. 
The results obtained from the evaluation parameters 
found to be within the specified limits of I.P. The  in 
vitro drug release characteristics were studied in 0.1N 
HCL for first 2hrs and phosphate buffer pH 6.8 for next 
3-12hrs  all  the  results  were  reported.  The  drug-
polymer  compatibility  studies  were  done  by  FTIR 
spectral  analysis.  All  the  tablets  were  found  to  be 
within the I.P limits. 
The drug and polymers were found to be compatible, 
the formulation A1 containing 25% Guar gum released 
85%  of  the  drug  in  12hrs,  while  the  formulation  A6 
containing 50% Guar gum release 30% of the drug in 
12hrs. 
The  formulation  B1  containing  5%  Carbopol-934 
released  89%  of  the  drug  in  12hrs,  while  the 
formulation  B6  containing  30%  Carbopol-934  release 
37% of the drug in 12hrs. 
Though  both  the  Natural  and  Synthetic  polymer 
retards  the  drug  release,  the  tablets  prepared  using 
Carbopol-934(5%)  require  lower  amount  and  better 
release  than  the  tablets  prepared  using  Guar  gum 
(25%).  The  drug  release  from  the  formulation  B1 
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